Singapore Institute of Advanced Medicine Holdings Ltd. (SG:9G2)
SGX:9G2
Want to see SG:9G2 full AI Analyst Report?
9G2 Stock Chart & Stats
S$0.07
S$0.00(0.00%)
At close: 4:00 PM EST
S$0.07
S$0.00(0.00%)
Day’s Range― - ―
52-Week RangeS$0.02 - S$0.09
Previous CloseN/A
Volume159.90K
Average Volume (3M)247.96K
Market Cap
S$56.65M
Enterprise ValueS$141.37M
Total Cash (Recent Filing)S$3.85M
Total Debt (Recent Filing)S$88.57M
Price to Earnings (P/E)―
Beta-0.16
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,231,494,600
10 Day Avg. Volume138,640
30 Day Avg. Volume247,960
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.55
Price to Sales (P/S)1.94
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA ~95% year-over-year revenue increase in 2025 shows meaningful market traction and demand for the company’s services. Sustained top-line growth over several quarters would support operating leverage and increase the runway for reaching structural profitability if cost discipline continues.
High Gross MarginsA sustained gross margin near 92% indicates very strong unit economics or favorable pricing/mix. High gross profitability provides a durable cushion to absorb SG&A and R&D, and creates a clearer path to positive operating leverage as revenue scales, assuming fixed costs are controlled.
Improving Free Cash Flow TrendA 91% improvement in free cash flow year-over-year signals improving operational efficiency or working capital management. While still negative, a persistent FCF improvement trend reduces near-term financing needs and, if maintained, materially lowers dilution and liquidity risk over the medium term.
Bears Say
Persistent Heavy LossesDeep and persistent operating and net losses (net margin near -167% in 2025) weaken shareholder returns and limit internal reinvestment capacity. Ongoing losses increase the probability of external financing, constraining long-term capital allocation and making profitability a multi-period execution challenge.
Structural Cash BurnConsecutive years of negative operating cash flow and multi-million dollar annual cash burn create durable financing needs. This elevates refinancing and dilution risk, restricts discretionary investment, and makes the company reliant on consistent external funding until operations deliver sustained positive cash generation.
Elevated And Rising LeverageSignificant historical leverage and a rebound to ~1.05 debt-to-equity in 2025 reduce financial flexibility. High leverage combined with negative earnings increases interest and refinancing risk, potentially forcing costly capital raises or limiting strategic options during adverse market or operational setbacks.
9G2 FAQ
What was Singapore Institute of Advanced Medicine Holdings Ltd.’s price range in the past 12 months?
Singapore Institute of Advanced Medicine Holdings Ltd. lowest share price was S$0.02 and its highest was S$0.09 in the past 12 months.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap?
Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap is S$56.65M.
When is Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date?
Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date is Nov 03, 2026 which is in 188 days.
How were Singapore Institute of Advanced Medicine Holdings Ltd.’s earnings last quarter?
Singapore Institute of Advanced Medicine Holdings Ltd. released its earnings results on Feb 13, 2026. The company reported -S$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.009.
Is Singapore Institute of Advanced Medicine Holdings Ltd. overvalued?
According to Wall Street analysts Singapore Institute of Advanced Medicine Holdings Ltd.’s price is currently Overvalued.
Does Singapore Institute of Advanced Medicine Holdings Ltd. pay dividends?
Singapore Institute of Advanced Medicine Holdings Ltd. does not currently pay dividends.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate?
Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Singapore Institute of Advanced Medicine Holdings Ltd. have?
Singapore Institute of Advanced Medicine Holdings Ltd. has 1,231,494,600 shares outstanding.
What happened to Singapore Institute of Advanced Medicine Holdings Ltd.’s price movement after its last earnings report?
Singapore Institute of Advanced Medicine Holdings Ltd. reported an EPS of -S$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Singapore Institute of Advanced Medicine Holdings Ltd.?
Currently, no hedge funds are holding shares in SG:9G2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Singapore Institute of Advanced Medicine Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.69%
12-Months-Change
Fundamentals
Return on Equity
-47.62%
Trailing 12-Months
Asset Growth
-7.63%
Trailing 12-Months
Company Description
Singapore Institute of Advanced Medicine Holdings Ltd.
Singapore Institute of Advanced Medicine Holdings Ltd. operates as a holding company with interest in providing healthcare services. It offers pharmaceutical, surgical supplies and medical laboratory services. The company was founded by Djeng Shih Kien on November 24, 2011 and is headquartered in Singapore.
Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) Earnings & Revenues
Technical Analysis
Raffles Medical Group
―
Thomson Medical Group Ltd.
―
HC Surgical Specialists Ltd
―
ISEC Healthcare Ltd
―
OUE Lippo Healthcare Limited
―